Peel Hunt reiterated their hold rating on shares of Hikma Pharmaceuticals Plc (LON:HIK) in a research report sent to investors on Thursday morning. The firm currently has a GBX 2,150 ($27.91) price target on the stock.
A number of other analysts have also commented on the company. Numis Securities Ltd reissued an add rating and set a GBX 1,560 ($20.25) price target on shares of Hikma Pharmaceuticals Plc in a research note on Friday, August 11th. Morgan Stanley lowered Hikma Pharmaceuticals Plc to an equal weight rating and cut their price target for the company from GBX 2,050 ($26.61) to GBX 1,600 ($20.77) in a research note on Wednesday, August 2nd. HSBC Holdings plc reissued a reduce rating and set a GBX 1,800 ($23.37) price target on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, July 4th. Barclays PLC reissued an overweight rating and set a GBX 2,200 ($28.56) price target on shares of Hikma Pharmaceuticals Plc in a research note on Monday, July 3rd. Finally, Citigroup Inc. reissued a neutral rating and set a GBX 1,550 ($20.12) price target on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, June 28th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of GBX 1,873.10 ($24.32).
Hikma Pharmaceuticals Plc (LON HIK) traded down 5.97% on Thursday, reaching GBX 1119.00. 1,474,853 shares of the company’s stock were exchanged. Hikma Pharmaceuticals Plc has a 52 week low of GBX 1,101.00 and a 52 week high of GBX 2,346.00. The company’s market cap is GBX 2.70 billion. The stock’s 50 day moving average is GBX 1,376.46 and its 200 day moving average is GBX 1,756.82.
ILLEGAL ACTIVITY NOTICE: “Hikma Pharmaceuticals Plc’s (HIK) Hold Rating Reaffirmed at Peel Hunt” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/18/hikma-pharmaceuticals-plcs-hik-hold-rating-reaffirmed-at-peel-hunt.html.
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.
